How to Monitor Cannabidiol Safety With Antidepressants in Youth
How should clinicians monitor safety and antidepressant interaction risk when using cannabidiol in young people with anxiety disorders?
Cannabidiol was generally well tolerated in this trial, but adverse events were common and were more likely when antidepressants were used concurrently. This guide applies to young people receiving adjunctive cannabidiol for treatment-resistant anxiety disorders and focuses on the monitoring approach actually used in the study.
-
Obtain baseline safety laboratory testing
Before treatment, obtain fasting bloodwork and review for clinically significant abnormalities that would argue against treatment. In the trial, routine safety tests included a full blood count, comprehensive metabolic panel, lipid panel, and thyroid function test.
-
Screen concomitant medications for interaction risk
Review current medications before starting CBD and avoid use with agents that either interact with CBD metabolism or are affected by CBD in ways that cannot be safely coadministered. The study specifically excluded patients on antipsychotics, anxiolytics, mood stabilizers, and other unsafe interacting medications.
-
Keep antidepressant dosing stable and document baseline use
If an antidepressant is continued, maintain a stable dose throughout the cannabidiol trial period, consistent with the study design. This is especially important because participants taking antidepressants were more likely to experience at least one adverse event.
-
Monitor at 4-week intervals during active treatment
See the patient every 4 weeks through week 12, with physician review at those same intervals, as was done in the trial. Repeat fasting blood draws every 4 weeks at baseline, week 4, week 8, and week 12 to monitor safety.
-
Ask directly about adverse effects at each visit
Use open-ended questioning about new symptoms and have a study physician or prescribing clinician review the events for possible relationship to CBD. In the trial, related or possibly related adverse events included fatigue, low mood, increased or decreased appetite, drowsiness, nausea, diarrhea, dry mouth, insomnia, and hot flushes or cold chills.
-
Adjust dose escalation when adverse events emerge
Use response and tolerability together when deciding whether to continue titration. In this study, some participants remained at 600 mg/day or 400 mg/day by week 12 based on treatment response and/or adverse events rather than being pushed to 800 mg/day.
-
Pay extra attention to escitalopram and citalopram
Be particularly alert when cannabidiol is combined with citalopram or escitalopram. In the trial, 5 of 6 participants taking one of these two antidepressants showed increased plasma concentrations after 12 weeks of CBD treatment.
Clinical Considerations
- Although no serious adverse events or clinically significant blood count, renal, or liver abnormalities were observed, adverse events were reported by 25 of 31 participants.
- Participants taking antidepressants were more likely to experience at least one adverse event, with an odds ratio of 6.4.
- The study's interaction signal was based on small numbers, particularly for citalopram and escitalopram.
- This monitoring workflow comes from a trial with close follow-up and regular laboratory testing, which may not be identical to every routine outpatient setting.
Bottom Line
When using adjunctive cannabidiol in young people with anxiety disorders, monitor every 4 weeks, track adverse effects actively, and watch particularly closely for interactions and tolerability problems in patients taking antidepressants, especially escitalopram or citalopram.
